Insulet price target raised to $293 from $245 at Stifel

Stifel raised the firm’s price target on Insulet (PODD) to $293 from $245 and keeps a Hold rating on the shares. Q4 sales outperformed Stifel and consensus forecasts, but represent the smallest “beat” since Q1 of FY22, though significant margin and EPS upside was “impressive,” the analyst tells investors. U.S. upside was modest, but guidance prompts the firm to raise 2025 estimates, though it still wants to better gauge T2 adoption versus what’s reflected in the current valuation, the analyst added.